Abstract

Non-small cell lung cancer (NSCLC) is a fatal disease, and its metastatic process is poorly understood. Although aberrant methylation is involved in tumor progression, the mechanisms underlying dynamic DNA methylation remain to be elucidated. It is significant to study the molecular mechanism of NSCLC metastasis and identify new biomarkers for NSCLC early diagnosis. Here, we performed MeDIP-seq and hMeDIP-seq analyses to detect the genes regulated by dynamic DNA methylation. Comparison of the 5mC and 5hmC sites revealed that the CD147 gene underwent active demethylation in NSCLC tissues compared with normal tissues, and this demethylation upregulated CD147 expression. Significantly high levels of CD147 expression and low levels of promoter methylation were observed in NSCLC tissues. Then, we identified the CD147 promoter as a target of KLF6, MeCP2, and DNMT3A. Treatment of cells with TGF-β triggered active demethylation involving loss of KLF6/MeCP2/DNMT3A and recruitment of Sp1, Tet1, TDG, and SMAD2/3 transcription complexes. A dCas9-SunTag-DNMAT3A-sgCD147-targeted methylation system was constructed to reverse CD147 expression. The targeted methylation system downregulated CD147 expression and inhibited NSCLC proliferation and metastasis in vitro and in vivo. Accordingly, we used cfDNA to detect the levels of CD147 methylation in NSCLC tissues and found that the CD147 methylation levels exhibited an inverse relationship with tumor size, lymphatic metastasis, and TNM stage. In conclusion, this study clarified the mechanism of active demethylation of CD147 and suggested that the targeted methylation of CD147 could inhibit NSCLC invasion and metastasis, providing a highly promising therapeutic target for NSCLC.

Highlights

  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and is associated with the highest cancer incidence and mortality rates of cancer worldwide [1]

  • We confirmed that compared with normal tissues, the CD147 gene in NSCLC tissues underwent an active demethylation process, and the decreased methylation led to the upregulation of CD147 expression

  • We found that the transcriptional regulatory complex of the CD147 gene differed between NSCLC tissues and normal tissues

Read more

Summary

INTRODUCTION

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and is associated with the highest cancer incidence and mortality rates of cancer worldwide [1]. We have previously NSCLC tissues, whereas the content of 5hmC exhibited the reported that promoter hypomethylation upregulates CD147 opposite trend (Fig. 1B) These results indicated that the CD147 expression and is associated with poor prognosis in patients with gene underwent increased levels of active demethylation in HCC [16]. These results indicated that hypomethylation of associated with tumor progression We hypothesized that it would the CD147 promoter region might participate in the increase in be worthwhile to determine whether CD147 methylation could be CD147 expression observed in NSCLC tissues. We further investigated the induce global changes in DNA demethylation This mechanism of active demethylation in CD147, used a targeted experiment was only semiquantitative, we consistently observed methylation system to reverse CD147 expression, and attempted obvious decreases in DNA methylation after 5-Aza-dC treatment to develop an effective clinical therapeutic target for NSCLC.

RESULTS
DISCUSSION
Findings
MATERIAL AND METHODS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call